<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00352911</url>
  </required_header>
  <id_info>
    <org_study_id>VT004</org_study_id>
    <nct_id>NCT00352911</nct_id>
  </id_info>
  <brief_title>Antiviral Activity and Safety of Mifepristone at 2 Doses in HIV-1 Infected Subjects</brief_title>
  <official_title>A Randomized, Placebo-controlled, Dose Escalating, Phase II Trial of the Anti -HIV-Activity and Safety of VGX-410 (Mifepristone) in HIV-1 Infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VGX Pharmaceuticals, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VGX Pharmaceuticals, LLC</source>
  <brief_summary>
    <textblock>
      The objective of the study is to determine whether mifepristone (VGX-410) has anti-HIV-1
      activity at doses of either 300 mg or 600 mg per day after oral administration for 14 days at
      each dose level.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      VT004 is a double-blind, randomized, placebo-controlled Phase II study of two doses of orally
      administered mifepristone (VGX-410) (300 and 600 mg) taken as a twice daily (BID) dosage
      (150mg BID and 300mg BID) in a dose-escalating fashion for 14 days at each dose level to
      determine antiviral activity and safety in HIV-1-infected participants. At entry, 18 subjects
      will be randomized in a 5:1 fashion (15 on active drug: 3 on placebo) to receive escalating
      doses of VGX-410 or matching placebo. Patients will be randomized to receive 300 mg (as 150
      mg BID dose) of VGX-410 or matching placebo for 14 days. In patients that complete this dose
      without significant safety concerns or side effects, the dose will be increased to 600 mg (as
      300 mg BID dose) or matching placebo for 14 days. Patients must meet all inclusion/exclusion
      criteria listed below and be seen on a weekly basis by study personnel while on study drug.
      Patients must return ~ one month after finishing the study therapy for examination and safety
      labs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Log Change in Viral Load From Baseline (Day 1) to Day 56</measure>
    <time_frame>Baseline (Day 1) to Day 56</time_frame>
    <description>Mean log change in HIV RNA viral load (significant reduction is considered &gt;0.5 log 10) from baseline (Day 1) to Day 56 following 150mg twice daily for 14 days, dose escalation to 300mg twice daily for 14 days and then 28 days off treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>VGX-410 (Mifepristone)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>150mg twice daily of VGX-410 for 14 days and, if well tolerated, a dose escalation to 300mg twice daily of VGX-410 for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for VGX-410 (Mifepristone)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>150mg twice daily of placebo for VGX-410 for 14 days and, if well tolerated, a dose escalation to 300mg twice daily of placebo for VGX-410 for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VGX-410 (Mifepristone)</intervention_name>
    <arm_group_label>VGX-410 (Mifepristone)</arm_group_label>
    <other_name>Mifeprex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for VGX-410 (Mifepristone)</intervention_name>
    <arm_group_label>Placebo for VGX-410 (Mifepristone)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infection

          -  CD4 cell count &gt; 200

          -  Plasma HIV-1 RNA &gt; 2000 copies/mL and have not received antiretroviral therapy within
             the 16 weeks prior to entry

          -  Absolute neutrophil count &gt; 750/mm3

          -  Hemoglobin &gt; 10 g/dL

          -  Platelet count &gt; 100,000 mm3

          -  Creatinine &lt; 2 X upper limit of normal [ULN] (fasting)

          -  AST (SGOT), ALT (SGPT), and alkaline phosphatase &lt; 2 X ULN

          -  Total bilirubin &lt; 2.5 X ULN

          -  Albumin &gt; 3 g/dL

          -  Serum lipase &lt; 1.5 X ULN

          -  Thyroid stimulating hormone (TSH) within normal limits

          -  Plasma cortisol &gt; 20 mcg/dL, 30 minutes after cosyntropin administration

          -  Negative pregnancy test and willing to use effective birth control during the study

          -  Karnofsky performance score &gt; 80 within 30 days prior to study entry

          -  Men and women &gt;= 18 years of age

        Exclusion Criteria:

          -  Receipt of antiretroviral treatment within the 16 weeks prior to study entry

          -  Chronic adrenal failure, adrenal insufficiency, personal or family history of
             autoimmune endocrine disease, history of active hepatitis B or C, or current treatment
             for hepatitis B virus (HBV) or hepatitis C virus (HCV)

          -  Presence of diabetes mellitus

          -  Pregnancy within 90 days prior to study entry or breast-feeding

          -  Dysfunctional uterine bleeding within the 12 months prior to study entry

          -  Any current hormonal contraception or intrauterine device (IUD) use

          -  Use of drugs that are inhibitors or inducers of metabolism by the cytochrome P450 3A4
             within 7 days prior to study entry

          -  Use of systemic corticosteroids or hormonal agents within 90 days prior to study entry

          -  Use of any immunomodulator, HIV vaccines, or investigational therapy within 90 days
             prior to study entry

          -  Any vaccination within 30 days prior to study entry

          -  Use of systemic cytotoxic chemotherapy within 90 days prior to study entry

          -  History of allergy to mifepristone or its formulations

          -  Active drug or alcohol use

          -  Serious illness requiring systemic treatment and/or hospitalization for at least 14
             days prior to study entry

          -  Weight &lt; 40 kg or 88 lbs. within 90 days prior to study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Princy Kumar, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Georgetown University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Valerianna Amorosa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Veteran's Hospital of Philadelphia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pablo Tebas, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2006</study_first_submitted>
  <study_first_submitted_qc>July 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2006</study_first_posted>
  <results_first_submitted>April 15, 2009</results_first_submitted>
  <results_first_submitted_qc>December 22, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 27, 2010</results_first_posted>
  <last_update_submitted>March 4, 2010</last_update_submitted>
  <last_update_submitted_qc>March 4, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2010</last_update_posted>
  <responsible_party>
    <organization>VGX Pharmaceuticals, LLC</organization>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>VGX-410 (Mifepristone)</title>
          <description>150mg twice daily for 14 days and if well tolerated, dose escalation to 300mg twice daily for 14 days</description>
        </group>
        <group group_id="P2">
          <title>Placebo for VGX-410 (Mifepristone)</title>
          <description>150mg twice daily for 14 days and if well tolerated, dose escalation to 300mg twice daily for 14 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>150mg Twice Daily (14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>300mg Twice Daily (14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>VGX-410 (Mifepristone)</title>
          <description>150mg twice daily for 14 days and if well tolerated, dose escalation to 300mg twice daily for 14 days</description>
        </group>
        <group group_id="B2">
          <title>Placebo for VGX-410 (Mifepristone)</title>
          <description>150mg twice daily for 14 days and if well tolerated, dose escalation to 300mg twice daily for 14 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.3" spread="8.0"/>
                    <measurement group_id="B2" value="37.7" spread="7.4"/>
                    <measurement group_id="B3" value="41.6" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Log Change in Viral Load From Baseline (Day 1) to Day 56</title>
        <description>Mean log change in HIV RNA viral load (significant reduction is considered &gt;0.5 log 10) from baseline (Day 1) to Day 56 following 150mg twice daily for 14 days, dose escalation to 300mg twice daily for 14 days and then 28 days off treatment.</description>
        <time_frame>Baseline (Day 1) to Day 56</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VGX-410 (Mifepristone)</title>
            <description>150mg twice daily for 14 days and if well tolerated, dose escalation to 300mg twice daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo for VGX-410 (Mifepristone)</title>
            <description>150mg twice daily for 14 days and if well tolerated, dose escalation to 300mg twice daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Log Change in Viral Load From Baseline (Day 1) to Day 56</title>
          <description>Mean log change in HIV RNA viral load (significant reduction is considered &gt;0.5 log 10) from baseline (Day 1) to Day 56 following 150mg twice daily for 14 days, dose escalation to 300mg twice daily for 14 days and then 28 days off treatment.</description>
          <units>copies/mL on log scale</units>
          <param>Log Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.28"/>
                    <measurement group_id="O2" value="0.42" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs that occurred during the treatment period (Days 1-28) of the study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>VGX-410 (Mifepristone)</title>
          <description>150mg twice daily for 14 days and if well tolerated, dose escalation to 300mg twice daily for 14 days</description>
        </group>
        <group group_id="E2">
          <title>Placebo for VGX-410 (Mifepristone)</title>
          <description>150mg twice daily for 14 days and if well tolerated, dose escalation to 300mg twice daily for 14 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngolaryngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Disorders</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food Allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Libido Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus Congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Rash Papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Skin and Subcutaneous Tissue Disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot Flush</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mary Giffear, Sr. Clinical Scientist</name_or_title>
      <organization>VGX Pharmaceuticals, LLC</organization>
      <phone>267 440 4220</phone>
      <email>mgiffear@inovio.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

